<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02526641</url>
  </required_header>
  <id_info>
    <org_study_id>HCV sCD163 AbbVie</org_study_id>
    <nct_id>NCT02526641</nct_id>
  </id_info>
  <brief_title>Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of Chronic Hepatitis C</brief_title>
  <official_title>New AbbVie Direct Acting Antiviral (DAA) Treatment of Chronic Hepatitis C Infection - Effects on the Macrophage Activation Marker Soluble CD163, Portal Hypertension, and Metabolic Liver Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of the effects of the new Abbvie direct acting anti-viral (DAA) treatment of
      chronic viral hepatitis C infection on the macrophage specific activation marker soluble
      CD163, portal hypertension determined by the hepatic venous pressure gradient (HVPG), and
      metabolic liver function determined by the galactose elimination capacity (GEC) test and the
      functional hepatic nitrogen clearance (FHNC).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the hepatic venous pressure gradient determined by liver vein catheterization from baseline to 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the hepatic venous pressure gradient determined by liver vein catheterization from baseline to 1 year</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the levels of the macrophage specific activation marker sCD163</measure>
    <time_frame>Before, during and after treatment - 60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in metabolic liver function determined by the galactose elimination capacity (GEC) test</measure>
    <time_frame>After 12 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the functional hepatic nitrogen clearance (FHNC)</measure>
    <time_frame>After 12 weeks treatment</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">16</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>AbbVie</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Functional Hepatic Nitrogen Clearance (FHNC)</intervention_name>
    <arm_group_label>AbbVie</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Galactose Elimination Capacity (GEC)</intervention_name>
    <arm_group_label>AbbVie</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver vein catheterization</intervention_name>
    <arm_group_label>AbbVie</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic hepatitis C patients initiating direct-acting anti-viral therapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hepatitis C genotype 1 or 4 patients initiating the new AbbVie treatment
             (paritaprevir, ritonavir, ombitasvir og dasabuvir sammen med ribavirin)

          -  Child-Pugh A liver cirrhosis

        Exclusion Criteria:

          -  Severe liver dysfunction - Child-Pugh klasse B-C

          -  Life expectancy less than 6 months

          -  planned liver transplantation or TIPS procedure within 6 months

          -  non-compliance to treatment or study procedures

          -  allergy to the DAA drugs used (paritaprevir, ritonavir, ombitasvir, dasabuvir, and
             ribavirin)

          -  pregnancy or expected pregnancy during the study (anti-conception has to be used)

          -  breast feeding

          -  portal vein thrombosis

          -  liver cancer or other malignancies

          -  alcohol consumption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Grønbæk, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Hepatology and Gastroenterology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2015</study_first_submitted>
  <study_first_submitted_qc>August 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2015</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Direct acting antiviral treatment</keyword>
  <keyword>sCD163</keyword>
  <keyword>Portal hypertension</keyword>
  <keyword>Metabolic liver function</keyword>
  <keyword>Cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

